 Home > Biochemistry News > Biotechnology News > Novartis announces overall survival data for MET inhibitors for first-line treatment of specific non-small cell lung cancer

Novartis announces overall survival data for MET inhibitors for first-line treatment of specific non-small cell lung cancer

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

ans 1 2

pleural effusion lung cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, at the American Society of Clinical Oncology (ASCO) in 2021, Novartis announced the latest oral high-selective small molecule MET inhibitor Tabrecta (capmatinib) in the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) Phase 2 clinical trial data

The results of the test showed that the median overall survival (OS) of the newly treated patients and the treated patients were 20.

In terms of safety, no new safety signals or unexpected safety results were observed

Lung cancer is the most common cancer in the world, with more than 2 million newly diagnosed cases each year

Note: The original text has been deleted

Reference materials:

[1] First Published Overall Survival and Updated Overall Response Data in Patients with METex14 metastatic NSCLC.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

ASCO first-line treatment of specific non-small cell lung cancer, Novartis announces overall survival data for MET inhibitors

06-17

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Novartis announces overall survival data for MET inhibitors for first-line treatment of specific non-small cell lung cancer

Related Articles

ASCO first-line treatment of specific non-small cell lung cancer, Novartis announces overall survival data for MET inhibitors